As it takes Lartruvo off the shelves, Lilly is setting up program to provide drug access to current patients
When Lilly’s approved soft tissue sarcoma drug Lartruvo unexpectedly failed to help patients live longer in a late-stage study in January, US and EU regulators discouraged new patients from starting treatment with the medicine, and the drugmaker suspended its promotion of the therapy.
Lartruvo was cleared for use by the FDA under the accelerated approval pathway — an increasingly popular mechanism used by the agency to hasten the pace of approvals — in 2016, and the confirmatory Phase III trial was intended to confirm the drug’s benefit. Since the trial was unsuccessful, Lilly was expected to rescind the drug from the market. On Thursday, the company $LLY said it was working on setting up a program so current patients can still access Lartruvo with “limited interruption” after it is officially withdrawn.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.